Quantitative analysis of p185(HER-2/neu) protein in breast cancer and its association with other prognostic factors. 1997

P F Valerón, and R Chirino, and V Vega, and O Falcón, and J F Rivero, and S Torres, and L León, and L Fernández, and J Pestano, and B Díaz-Chico, and J C Díaz-Chico
Department of Cellular and Molecular Endocrinology, University of Las Palmas de Gran Canaria, Canary Islands, Spain.

The total cellular p185(HER-2/neu) protein (p185) content was measured by ELISA in 346 invasive primary breast cancers, and the results were compared with those of estrogen (ER) and progesterone (PR) receptors, pS2 and Cathepsin D (Cat D) content. At a cut-off level of 260 fmol/mg protein, 53 of the 346 tumors (15%) were p185-positive. A significant positive correlation was observed between p185 levels and those of Cat D, and a weaker, though significant, positive correlation with ER, and pS2 levels, but not with those of PR. However, when only the 293 p185-negative tumors were considered, the correlation between p185 and ER improved substantially, and statistical significance was reached for PR. p185-positive tumors exhibited lower ER and PR content and higher Cat D content than p185-negative tumors. The pS2 content, in contrast, did not undergo significant variation. Tumors considered to be p185-positive were significantly more frequently positive for Cat D at the cut-off of 45 pmol/mg protein, and were more frequently negative for ER and/or PR, but only significant at the cut-off of 15 fmol/mg or higher for both steroid receptors. Finally, p185 status was not associated with menopausal status, tumor size, axillary-lymph-node invasiveness or distant metastases. These results suggest that 260 fmol/mg protein as the cut-off for p185 allows the identification of a tumoral sub-population with a more aggresive phenotype.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011506 Proteins Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. Gene Products, Protein,Gene Proteins,Protein,Protein Gene Products,Proteins, Gene
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D011980 Receptors, Progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives. Progesterone Receptors,Progestin Receptor,Progestin Receptors,Receptor, Progesterone,Receptors, Progestin,Progesterone Receptor,Receptor, Progestin
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002402 Cathepsin D An intracellular proteinase found in a variety of tissue. It has specificity similar to but narrower than that of pepsin A. The enzyme is involved in catabolism of cartilage and connective tissue. EC 3.4.23.5. (Formerly EC 3.4.4.23).
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females

Related Publications

P F Valerón, and R Chirino, and V Vega, and O Falcón, and J F Rivero, and S Torres, and L León, and L Fernández, and J Pestano, and B Díaz-Chico, and J C Díaz-Chico
August 1991, International journal of cancer,
P F Valerón, and R Chirino, and V Vega, and O Falcón, and J F Rivero, and S Torres, and L León, and L Fernández, and J Pestano, and B Díaz-Chico, and J C Díaz-Chico
June 2024, Molecular biology reports,
P F Valerón, and R Chirino, and V Vega, and O Falcón, and J F Rivero, and S Torres, and L León, and L Fernández, and J Pestano, and B Díaz-Chico, and J C Díaz-Chico
January 2007, In vivo (Athens, Greece),
P F Valerón, and R Chirino, and V Vega, and O Falcón, and J F Rivero, and S Torres, and L León, and L Fernández, and J Pestano, and B Díaz-Chico, and J C Díaz-Chico
November 1995, Journal of the Formosan Medical Association = Taiwan yi zhi,
P F Valerón, and R Chirino, and V Vega, and O Falcón, and J F Rivero, and S Torres, and L León, and L Fernández, and J Pestano, and B Díaz-Chico, and J C Díaz-Chico
June 2005, Cancer research and treatment,
P F Valerón, and R Chirino, and V Vega, and O Falcón, and J F Rivero, and S Torres, and L León, and L Fernández, and J Pestano, and B Díaz-Chico, and J C Díaz-Chico
January 2008, Journal of Ayub Medical College, Abbottabad : JAMC,
P F Valerón, and R Chirino, and V Vega, and O Falcón, and J F Rivero, and S Torres, and L León, and L Fernández, and J Pestano, and B Díaz-Chico, and J C Díaz-Chico
December 1992, International journal of oncology,
P F Valerón, and R Chirino, and V Vega, and O Falcón, and J F Rivero, and S Torres, and L León, and L Fernández, and J Pestano, and B Díaz-Chico, and J C Díaz-Chico
October 2002, International journal of cancer,
P F Valerón, and R Chirino, and V Vega, and O Falcón, and J F Rivero, and S Torres, and L León, and L Fernández, and J Pestano, and B Díaz-Chico, and J C Díaz-Chico
January 2011, Turk patoloji dergisi,
P F Valerón, and R Chirino, and V Vega, and O Falcón, and J F Rivero, and S Torres, and L León, and L Fernández, and J Pestano, and B Díaz-Chico, and J C Díaz-Chico
August 1992, Journal of the National Cancer Institute,
Copied contents to your clipboard!